Kineta, Inc. (OTC: KANT), relating to the proposed merger with TuHURA Biosciences, Inc. Under the terms of the agreement, TuHURA would acquire the rights to Kineta’s novel KVA12123 antibody for a combination of cash and shares of TuHURA common stock.